Chris Heery, Arcellx CMO
#ASCO22: Unconcerned with later market entry, Arcellx on the up with new BCMA CAR-T data
Arcellx $ACLX has been trading up more than 25% in the last five days, thanks to an ASCO abstract for its Phase I trial for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
